These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11595564)

  • 21. Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?
    Schilders JE; Wu H; Boomsma F; van den Meiracker AH; Danser AH
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):335-45. PubMed ID: 24958603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction.
    Jugdutt BI; Idikio H; Uwiera RR
    Mol Cell Biochem; 2007 Sep; 303(1-2):27-38. PubMed ID: 17426929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril.
    Ciulla MM; Paliotti R; Esposito A; Cuspidi C; Muiesan ML; Rosei EA; Magrini F; Zanchetti A
    J Hypertens; 2009 Mar; 27(3):626-32. PubMed ID: 19262230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.
    Hasvold LP; Bodegård J; Thuresson M; Stålhammar J; Hammar N; Sundström J; Russell D; Kjeldsen SE
    J Hum Hypertens; 2014 Nov; 28(11):663-9. PubMed ID: 25211055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
    Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
    Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
    White M; Rouleau JL; Afzal R; Floras J; Yusuf S; McKelvie RS
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):113-21. PubMed ID: 19299427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats.
    Nakamura Y; Ono H; Zhou X; Frohlich ED
    Hypertension; 2001 May; 37(5):1262-7. PubMed ID: 11358938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of candesartan, enalapril and their combination in congestive heart failure].
    Rapezzi C
    Ital Heart J Suppl; 2000 Mar; 1(3):429-30. PubMed ID: 10815278
    [No Abstract]   [Full Text] [Related]  

  • 31. Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
    Matsuo T; Ishikawa E; Ohta M; Shibouta Y; Ishimura Y; Imura Y; Sugiyama Y
    Jpn J Pharmacol; 2002 Mar; 88(3):300-6. PubMed ID: 11949885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.
    McKelvie RS; Yusuf S; Pericak D; Avezum A; Burns RJ; Probstfield J; Tsuyuki RT; White M; Rouleau J; Latini R; Maggioni A; Young J; Pogue J
    Circulation; 1999 Sep; 100(10):1056-64. PubMed ID: 10477530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M; Høj Nielsen A; Strandgaard S; Kamper AL
    Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats.
    Coppey LJ; Davidson EP; Rinehart TW; Gellett JS; Oltman CL; Lund DD; Yorek MA
    Diabetes; 2006 Feb; 55(2):341-8. PubMed ID: 16443766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart.
    Siddiqui AJ; Mansson-Broberg A; Gustafsson T; Grinnemo KH; Dellgren G; Hao X; Fischer H; Sylvén C
    Am J Hypertens; 2005 Oct; 18(10):1347-52. PubMed ID: 16202860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
    Phakdeekitcharoen B; Leelasa-nguan P
    Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
    Schmidt A; Gruber U; Böhmig G; Köller E; Mayer G
    Nephrol Dial Transplant; 2001 May; 16(5):1034-7. PubMed ID: 11328912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis.
    Tuncer I; Ozbek H; Ugras S; Bayram I
    Exp Toxicol Pathol; 2003 Sep; 55(2-3):159-66. PubMed ID: 14620537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats.
    Miki S; Takeda K; Hatta T; Harada S; Kido H; Oguni A; Moriguchi J; Morimoto S; Kawa T; Sasaki S; Nakagawa M
    Am J Hypertens; 2002 Mar; 15(3):286-90. PubMed ID: 11939622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
    Hamai M; Iwai M; Ide A; Tomochika H; Tomono Y; Mogi M; Horiuchi M
    Neuropharmacology; 2006 Sep; 51(4):822-8. PubMed ID: 16824557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.